Lipocine Debt-to-Equity Ratio Growth & History (LPCN)
Lipocine's debt-to-equity ratio was 0.04 for fiscal 2021.
View full Lipocine company overviewLipocine annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2021 | 2021-12-31 | 0.04 | −0.33 | −89.96% |
| 2020 | 2020-12-31 | 0.36 | −0.77 | −67.95% |
| 2019 | 2019-12-31 | 1.14 | 0.05 | +4.52% |
| 2018 | 2018-12-31 | 1.09 | 1.09 | — |
| 2017 | 2017-12-31 | 0.00 | — | — |
Lipocine quarterly debt-to-equity ratio
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q1 2022 | 2022-03-31 | 0.02 | −0.09 | −82.57% |
| Q4 2021 | 2021-12-31 | 0.04 | −0.33 | −89.96% |
| Q3 2021 | 2021-09-30 | 0.08 | −0.36 | −82.61% |
| Q2 2021 | 2021-06-30 | 0.09 | −0.39 | −80.74% |
| Q1 2021 | 2021-03-31 | 0.11 | −0.86 | −88.38% |
| Q4 2020 | 2020-12-31 | 0.36 | −0.77 | −67.95% |
| Q3 2020 | 2020-09-30 | 0.44 | −0.62 | −58.56% |
| Q2 2020 | 2020-06-30 | 0.48 | −0.40 | −45.30% |
| Q1 2020 | 2020-03-31 | 0.97 | 0.21 | +28.22% |
| Q4 2019 | 2019-12-31 | 1.14 | 0.05 | +4.52% |
| Q3 2019 | 2019-09-30 | 1.06 | 0.19 | +21.98% |
| Q2 2019 | 2019-06-30 | 0.88 | 0.16 | +21.25% |
| Q1 2019 | 2019-03-31 | 0.76 | 0.15 | +25.29% |
| Q4 2018 | 2018-12-31 | 1.09 | 1.09 | — |
| Q3 2018 | 2018-09-30 | 0.87 | — | — |
| Q2 2018 | 2018-06-30 | 0.73 | — | — |
| Q1 2018 | 2018-03-31 | 0.60 | — | — |
| Q4 2017 | 2017-12-31 | 0.00 | — | — |
Lipocine debt-to-equity ratio trends
Between the periods ended 2017-12-31 and 2021-12-31, Lipocine's debt-to-equity ratio increased from 0.00 to 0.04, a change of 0.04. The latest reported quarter, Q1 2022, shows 0.02.
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lipocine source filings ↗